- Home
- JGH vs SGHT Comparison
JGH vs SGHT Comparison
Compare JGH & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JGH
- SGHT
- Stock Information
- Founded
- JGH 2014
- SGHT 2011
- Country
- JGH United States
- SGHT United States
- Employees
- JGH N/A
- SGHT N/A
- Industry
- JGH Investment Managers
- SGHT Medical Specialities
- Sector
- JGH Finance
- SGHT Health Care
- Exchange
- JGH Nasdaq
- SGHT Nasdaq
- Market Cap
- JGH 308.3M
- SGHT 304.4M
- IPO Year
- JGH N/A
- SGHT 2021
- Fundamental
- Price
- JGH $12.79
- SGHT $3.61
- Analyst Decision
- JGH
- SGHT Buy
- Analyst Count
- JGH 0
- SGHT 7
- Target Price
- JGH N/A
- SGHT $6.27
- AVG Volume (30 Days)
- JGH 73.9K
- SGHT 206.9K
- Earning Date
- JGH 01-01-0001
- SGHT 11-07-2024
- Dividend Yield
- JGH 9.85%
- SGHT N/A
- EPS Growth
- JGH N/A
- SGHT N/A
- EPS
- JGH N/A
- SGHT N/A
- Revenue
- JGH N/A
- SGHT $79,543,000.00
- Revenue This Year
- JGH N/A
- SGHT $2.13
- Revenue Next Year
- JGH N/A
- SGHT $7.99
- P/E Ratio
- JGH N/A
- SGHT N/A
- Revenue Growth
- JGH N/A
- SGHT N/A
- 52 Week Low
- JGH $10.36
- SGHT $3.30
- 52 Week High
- JGH $12.85
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- JGH 32.79
- SGHT 41.47
- Support Level
- JGH $12.65
- SGHT $3.45
- Resistance Level
- JGH $13.38
- SGHT $3.64
- Average True Range (ATR)
- JGH 0.13
- SGHT 0.19
- MACD
- JGH -0.06
- SGHT 0.03
- Stochastic Oscillator
- JGH 18.49
- SGHT 38.04
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.